WGS
$69.84-3.16 (-4.33%)
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Recent News
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC
GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra Therapeutics (NASDAQ:ZVRA) announced a new partnership to launch a sponsored genetic testing program for NPC (Niemann-Pick disease type C). This aims to expand access to GeneDx’s ExomeDx test for patients in the US who […]
New Strong Buy Stocks for March 18th
NWPX, INNV, WGS, BCBP and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on March 18, 2026.
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?
In March 2026, GeneDx Holdings Corp. announced a Niemann-Pick disease type C sponsored genetic testing program with Zevra Therapeutics, expanding access to ExomeDx at no cost for eligible U.S. patients and contributing de-identified data to GeneDx Infinity to support faster and more accurate NPC diagnoses. This collaboration strengthens Zevra’s position in rare disease care by directly linking broader genetic testing and earlier NPC identification to potential treatment decisions for its...
Is GeneDx Holdings (WGS) Pricing In Its Sharp 27% Weekly Share Price Move?
If you are wondering whether GeneDx Holdings is pricing in its full potential or still offering room for value, the stock's recent track record gives you a lot to think about. The share price closed at US$94.51, with a 27.4% move over the last 7 days and 12.1% over the last 30 days, set against a year to date return of a 28.6% decline and a 5.4% gain over the past year, while the 3 year return is very large and the 5 year return shows an 84.1% decline. Recent pricing shifts sit against a...